| 1. |
Sen A, Jette N, Husain M, et al. Epilepsy in older people. The Lancet, 2020, 395(10225): 735-748.
|
| 2. |
Ghosh S, Jehi LE. New-onset epilepsy in the elderly: challenges for the internist. Cleve Clin J Med, 2014, 81(8): 490-498.
|
| 3. |
Lezaic N, Roussy J, Masson H, et al. Epilepsy in the elderly: Unique challenges in an increasingly prevalent population. Epilepsy & Behavior, 2020, 102: 1-12.
|
| 4. |
Rosenow F, Brandt C, Bozorg A, et al. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurologica Scandinavica, 2020, 141(6): 473-482.
|
| 5. |
Shih JJ, Whitlock JB, Chimato N, et al. Epilepsy treatment in adults and adolescents: Expert opinion, 2016. Epilepsy & Behavior, 2017, 69: 186-222.
|
| 6. |
Lattanzi S, Trinka E, Del Giovane C, et al. Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta‐analysis. Epilepsia, 2019, 60(11): 2245-2254.
|
| 7. |
Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
|
| 8. |
Holtkamp D, Opitz T, Niespodziany I, et al. Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na+ channel inactivation. Epilepsia, 2017, 58(1): 27-41.
|
| 9. |
Wang X, Yu Y, Ma R, et al. Lacosamide modulates collapsin response mediator protein 2 and inhibits mossy fiber sprouting after kainic acid-induced status epilepticus. Neuro Report, 2018, 29(16): 1384-1390.
|
| 10. |
Fukuyama K, Ueda Y, Okada M. Effects of Carbamazepine, lacosamide and zonisamide on gliotransmitter release associated with activated astroglial hemichannels. Pharmaceuticals, 2020, 13(6): 117.
|
| 11. |
Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clinical Pharmacokinetics, 2015, 54(9): 901-914.
|
| 12. |
Cawello W, Fuhr U, Hering U, et al. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. Clinical Pharmacokinetics, 2013, 52(10): 897-906.
|
| 13. |
Asconapé J J. Use of antiepileptic drugs in hepatic and renal disease. Handbook of Clinical Neurology. Elsevier. 2014: 417-432.
|
| 14. |
Cawello W, Stockis A, Andreas JO, et al. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci, 2014, 1329: 18-32.
|
| 15. |
De Biase S, Valente M, Gigli GL, et al. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures. Expert Opinion on Drug Metabolism & Toxicology, 2017, 13(9): 997-1005.
|
| 16. |
Villanueva V, Giráldez BG, Toledo M, et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurologica Scandinavica, 2018, 138(3): 186-194.
|
| 17. |
Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. The Lancet Neurology, 2017, 16(1): 43-54.
|
| 18. |
Del Bianco C, Placidi F, Liguori C, et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy & Behavior, 2019, 94: 178-182.
|
| 19. |
Kim DW, Kim HK, Bae EK. Switching from traditional sodium channel blockers to lacosamide in patients with epilepsy. Seizure, 2019, 65: 172-175.
|
| 20. |
Runge U, Arnold S, Brandt C, et al. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study. Epilepsia, 2015, 56(12): 1921-1930.
|
| 21. |
Villanueva V, Garcés M, López-Gomáriz E, et al. Early add-on lacosamide in a real-life setting: results of the REALLY study. Clinical drug investigation, 2015, 35(2): 121-131.
|
| 22. |
Muñoz-Lopetegi A, López-González FJ, Rodríguez-Osorio X, et al. LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting. Epilepsy Research, 2018, 145: 51-54.
|
| 23. |
Rainesalo S, Mäkinen J, Raitanen J, et al. Clinical management of elderly patients with epilepsy; the use of lacosamide in a single center setting. Epilepsy & Behavior, 2017, 75: 86-89.
|
| 24. |
Sarkis RA, Nicolas J, Lee JW. Tolerability of lacosamide or zonisamide in elderly patients with seizures. Seizure, 2017, 49: 1-4.
|
| 25. |
Choi H, Thacker EL, Longstreth WT Jr, et al. Cognitive decline in older adults with epilepsy: The Cardiovascular Health Study. Epilepsia, 2020, Nov 23, Online ahead of print.
|
| 26. |
Jff DM, van Veenendaal TM, Majoie HJ, et al. Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. Acta Neurologica Scandinavica, 2015, 131(6): 347-354.
|
| 27. |
Lancman ME, Fertig EJ, Trobliger RW, et al. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy. Epilepsy & Behavior, 2016, 61: 27-33.
|
| 28. |
Gul A, Mehreen S. Effectiveness of Lacosamide on everyday cognitive deficits, psychiatric symp-toms and resilience in patients with epilepsy. 2020, 70(9): 1611-1615.
|
| 29. |
Liguori C, Izzi F, Manfredi N, et al. Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine. Epilepsy & behavior case reports, 2018, 10: 35-37.
|
| 30. |
Meador KJ, Loring DW, Boyd A, et al. Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine. Epilepsy & Behavior, 2016, 62: 267-275.
|
| 31. |
Helmstaedter C, Witt JA. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepsy & Behavior, 2013, 26(2): 182-187.
|
| 32. |
Meschede C, Witt JA, Rademacher M, et al. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure, 2018, 58: 141-146.
|
| 33. |
Moseley BD, Cole D, Iwuora O, et al. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Research, 2015, 110: 115-118.
|
| 34. |
Rocamora R, Ley M, Molins A, et al. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study. Epilepsy & Behavior, 2018, 79: 87-92.
|
| 35. |
Alfaro A, Asensio M, García-Escrivá A, et al. LAM study: Effects of lacosamide on behaviour and quality of life in patients with epilepsy. Neurología (English Edition), 2019, 34(1): 1-6.
|
| 36. |
Corbellini ÁB, Torre PP, Hristova VN, et al. Cardioembolic acute cerebral micro‐infarcts in the context of atrial fibrillation after low‐dose intravenous infusion of lacosamide. Epileptic Disorders, 2020, 22(1): 83-89.
|
| 37. |
Lachuer C, Corny J, Bézie Y, et al. Complete atrioventricular block in an elderly patient treated with low-dose lacosamide. Cardiovascular toxicology, 2018, 18(6): 579-582.
|
| 38. |
Ng PC, Schimmel J, Wang GS. Lacosamide overdose: a case of QRS prolongation and seizure. The Journal of emergency medicine, 2019, 56(6): 652-656.
|
| 39. |
Berei TJ, Lillyblad MP, Almquist AK. Lacosamide-induced recurrent ventricular tachycardia in the acute care setting. Journal of pharmacy practice, 2018, 31(2): 222-226.
|
| 40. |
Matsudaira T, Terada T, Araki Y, et al. HyperCKemia associated with lacosamide therapy in an elderly patient with focal onset epilepsy. Seizure, 2018, 63: 14-16.
|
| 41. |
Gupta SS, Patti R, Lindsay D, et al. Lacosamide: Associated hyponatremia. American journal of therapeutics, 2018, 25(6): e729-e730.
|
| 42. |
Simko J, Fekete S, Malakova J, et al. The effect of lacosamide on bone tissue in orchidectomised male albino Wistar rats. Biomedical Papers, 2015, 159(3): 394-399.
|
1/5
WeChat